central nervous system disease: A disease involving the central nervous system.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
428 |
4. Check minimum number of eventsNone |
428 |
5. Include endpointsNone |
428 |
6. Filter based on genotype QC (FinnGen only) |
428 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G90-G99
- Name in latin
- Aliae morbositates systematis nervosi centralis
Similar endpoints
↥List of similar endpoints to
Other disorders of central nervous system
based on the number of shared cases.
Similar with more cases:
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3599 | 1799 | 1755 |
| Only index persons | 2683 | 1459 | 1224 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.05 | 0.05 |
| Only index persons | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 51.05 | 50.08 | 51.69 |
| Only index persons | 46.73 | 46.94 | 46.48 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 428 | 259 | 169 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.07 |
| Median age at first event (years) | 48.08 | 45.14 | 52.58 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 381
- Matched controls
- 3807
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G96.0
ICD-10 Finland
Cerebrospinal fluid leak
+∞
200.2
174
*
G96.9
ICD-10 Finland
Disorder of central nervous system, unspecified
+∞
96.0
88
*
3499X
ICD-9 Finland
Other and unspecified disorders of the nervous system, Unspecified disorders of nervous system
+∞
75.6
70
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
9.4
43.4
96
131
AA1AD
NOMESCO Finland
CT of head and brain
5.3
39.7
148
410
G96.8
ICD-10 Finland
Other specified disorders of central nervous system
+∞
36.0
34
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
8.6
33.5
77
109
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
60.0
32.9
38
7
TAB00
NOMESCO Finland
Lumbar puncture
9.1
27.2
59
75
AAK40
NOMESCO Finland
Closure of cerebrospinal fluid fistula
290.3
27.1
27
*
R51.80
ICD-10 Finland
Headache
4.4
24.9
101
286
G96.1
ICD-10 Finland
Disorders of meninges, not elsewhere classified
+∞
21.0
20
*
TAA40
NOMESCO Finland
Cathetrisation of cerebrospinal fluid through skin
110.8
19.8
21
*
M03BX01
ATC
baclofen; systemic
14.3
19.6
33
25
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
15.1
19.4
32
23
N03AX12
ATC
gabapentin; oral
3.9
18.9
87
270
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.6
18.1
37
42
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
22.2
17.5
25
12
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.8
16.4
57
135
N03AX16
ATC
pregabalin; oral
2.9
15.7
115
497
UDH02
NOMESCO Finland
Rhinopharyngoscopy
5.1
15.3
50
110
ZXC95
NOMESCO Finland
Use of surgical navigator
17.4
14.9
23
14
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.1
14.7
61
171
AAE05
NOMESCO Finland
Nasoendoscopic closure of cerebrospinal fluid fistula
+∞
14.7
14
*
R1250
NOMESCO Finland
Evaluation of functional capability
9.7
14.5
29
32
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
28.4
14.4
19
7
XA800
NOMESCO Finland
Neuropsychological investigation
6.0
14.4
40
73
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.6
14.1
42
83
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
24.9
13.9
19
8
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.7
13.6
107
476
X59
ICD-10 Finland
Exposure to unspecified factor
3.0
13.6
90
359
AAK10
NOMESCO Finland
Repair of dura
+∞
13.6
13
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.5
13.1
65
212
G00.9
ICD-10 Finland
Bacterial meningitis, unspecified
+∞
12.6
12
*
N03AF02
ATC
oxcarbazepine; oral
7.1
12.5
30
45
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.7
12.4
56
169
XCK00
NOMESCO Finland
Perimetry
4.7
12.3
42
97
G82.2
ICD-10 Finland
Paraplegia, unspecified
38.9
12.3
15
*
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
6.4
12.2
32
54
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
9.8
12.2
24
26
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.3
12.1
37
76
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.2
12.0
68
244
S18
ICPC
Laceration/cut
2.2
11.8
170
1019
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
11.7
166
988
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
+∞
11.5
11
*
N03AX14
ATC
levetiracetam; systemic
7.5
11.2
26
37
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
25.9
11.2
15
6
N03AE01
ATC
clonazepam; systemic
4.6
11.0
38
89
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
10.9
126
677
AWB00
NOMESCO Finland
Reoperation for superficial infection in surgery of the nervous system
61.7
10.7
12
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.0
10.5
42
114
T91.3
ICD-10 Finland
Sequelae of injury of spinal cord
112.9
10.5
11
*
ZZC00
NOMESCO Finland
Graft of fascia
+∞
10.5
10
*
N02AX02
ATC
tramadol; systemic, rectal
2.1
10.4
166
1024
R20.2
ICD-10 Finland
Paraesthesia of skin
4.3
10.3
38
96
H02AB09
ATC
hydrocortisone; systemic
6.8
10.2
25
39
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.6
10.1
78
339
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
15.1
10.1
16
11
UDM02
NOMESCO Finland
Sinoscopy
7.7
9.8
22
30
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
13.8
9.7
16
12
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
13.8
9.7
16
12
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
9.7
87
410
L89
ICD-10 Finland
Decubitus ulcer and pressure area
11.8
9.6
17
15
XKC03
NOMESCO Finland
Water cystometry
6.0
9.4
25
44
AA1BD
NOMESCO Finland
Extensive CT of head and brain
7.0
9.3
22
33
XKD06
NOMESCO Finland
Physiologic investigation of micturition
7.0
9.3
22
33
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
16.1
9.1
14
9
N06CA01
ATC
amitriptyline and psycholeptics; systemic
3.1
9.0
51
182
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
19.1
9.0
13
7
WX882
NOMESCO Finland
High dependency care
5.6
8.9
25
47
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.3
8.9
44
143
R4110
NOMESCO Finland
Physiotherapy
2.2
8.9
108
587
109
Kela drug reimbursment
Multiple sclerosis
11.1
8.9
16
15
G35
ICD-10 Finland
Multiple sclerosis
7.9
8.7
19
25
G03.9
ICD-10 Finland
Meningitis, unspecified
51.1
8.7
10
*
A28
ICPC
Limited function/disability NOS
2.7
8.5
60
247
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
13.1
8.4
14
11
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
+∞
8.4
8
*
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
+∞
8.4
8
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.3
8.3
87
437
ZZF00
NOMESCO Finland
Graft of adipose tissue
14.9
8.3
13
9
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
8.2
63
269
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
3.8
8.2
34
96
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
22.6
8.1
11
5
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.7
8.0
34
98
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.0
8.0
17
22
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.6
7.9
26
59
R4130
NOMESCO Finland
Speech therapy
9.7
7.8
15
16
TDM10
NOMESCO Finland
Puncture of maxillary antrum
4.6
7.8
26
60
R11
ICD-10 Finland
Nausea and vomiting
3.4
7.8
36
112
H47.2
ICD-10 Finland
Optic atrophy
45.9
7.7
9
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.6
7.7
58
247
S02.10
ICD-10 Finland
Fracture of base of skull, closed
25.6
7.6
10
*
AA1AA
NOMESCO Finland
Head X-ray examination
25.6
7.6
10
*
R50.9
ICD-10 Finland
Fever, unspecified
2.4
7.5
67
311
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
6.0
7.3
19
33
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
+∞
7.3
7
*
AAF25
NOMESCO Finland
Removal of shunt of ventricle of brain
+∞
7.3
7
*
H02AB06
ATC
prednisolone; systemic
1.8
7.3
176
1218
L28
ICPC
Limited function/disability (L)
2.4
7.3
64
297
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
16.1
7.3
11
7
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.2
7.2
37
124
J01EA01
ATC
trimethoprim; systemic
2.0
7.2
102
583
N18
ICPC
Paralysis/weakness
8.2
7.2
15
19
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
4.5
7.2
24
56
R01AD08
ATC
fluticasone; nasal
2.0
7.1
114
683
R42
ICD-10 Finland
Dizziness and giddiness
2.1
7.0
81
425
N02BE01
ATC
paracetamol; systemic, rectal
2.0
7.0
313
2644
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.5
6.9
56
247
R55
ICD-10 Finland
Syncope and collapse
2.7
6.8
46
182
ZXA05
NOMESCO Finland
Left side
2.0
6.8
95
538
TKC20
NOMESCO Finland
Catheterisation of bladder
3.1
6.7
36
125
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.5
6.7
30
91
L03AX13
ATC
glatiramer acetate; parenteral
23.0
6.7
9
*
N06AB04
ATC
citalopram; systemic
2.1
6.7
84
458
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
5.0
6.6
20
42
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.6
6.6
48
199
R53
ICD-10 Finland
Malaise and fatigue
2.1
6.6
83
451
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
5.5
6.5
18
34
J01DA01
ATC
[U] cefalexin; systemic
1.8
6.5
239
1863
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
4.8
6.5
20
43
CS494
NOMESCO Finland
Other visual field testing
7.6
6.5
14
19
ZX120
NOMESCO Finland
Intravenous
2.7
6.4
44
176
T90.5
ICD-10 Finland
Sequelae of intracranial injury
14.6
6.4
10
7
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
14.6
6.4
10
7
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
14.6
6.4
10
7
N02AA05
ATC
oxycodone; systemic
2.4
6.4
56
259
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.0
6.4
94
541
M54.4
ICD-10 Finland
Lumbago with sciatica
2.3
6.3
62
302
N04BB01
ATC
amantadine; oral
9.5
6.3
12
13
L03AB07
ATC
interferon beta-1a; parenteral
18.4
6.3
9
5
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
18.4
6.3
9
5
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
6.3
88
497
G82.1
ICD-10 Finland
Spastic paraplegia
+∞
6.3
6
*
G00.1
ICD-10 Finland
Pneumococcal meningitis
+∞
6.3
6
*
T85.0
ICD-10 Finland
Mechanical complication of ventricular intracranial (communicating) shunt
+∞
6.3
6
*
G93.2
ICD-10 Finland
Benign intracranial hypertension
+∞
6.3
6
*
G95.0
ICD-10 Finland
Syringomyelia and syringobulbia
+∞
6.3
6
*
AAK00
NOMESCO Finland
Cranioplasty
+∞
6.3
6
*
AWC00
NOMESCO Finland
Reoperation of nervous system because of deep wound infection in the nervous system
+∞
6.3
6
*
J01DB01
ATC
cefalexin; oral
1.9
6.2
307
2612
H53.2
ICD-10 Finland
Diplopia
5.9
6.2
16
28
J45.9
ICD-10 Finland
Asthma, unspecified
2.1
6.2
71
371
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
5.0
6.1
18
37
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
12.8
6.1
10
8
N30.9
ICD-10 Finland
Cystitis, unspecified
3.4
6.1
28
88
N06AA09
ATC
amitriptyline; systemic
2.5
6.0
48
211
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
74
68
12.95
71.40
1.6
1.4
3.6
3.6
mmol/l
0.07
69
62
48
22
24.45
65.81
1.7
1.3
—
—
—
0
0
70
67
12.30
65.62
1.7
1.4
378.7
6.7
e6/l
1.39
62
55
70
67
12.30
65.62
1.7
1.4
5753.4
259.4
e6/l
0.88
62
56
32
12
28.74
46.85
1.5
1.3
—
—
—
0
0
114
441
3.16
22.43
1.9
2.3
28.8
29.6
s
1.16
109
425
24
23
11.00
21.97
1.1
1.0
—
—
—
0
0
91
312
3.43
21.78
6.8
8.7
14.5
12.2
kpa
2.73
86
299
91
312
3.43
21.78
6.8
8.7
5.2
5.2
kpa
0.01
86
297
255
1530
2.65
21.25
8.3
6.5
1.2
1.2
mmol/l
1.04
226
1293
238
1387
2.61
20.98
8.7
6.1
1.2
1.2
mmol/l
1.40
223
1262
88
314
3.27
19.62
7.0
8.8
0.5
1.4
mmol/l
0.86
69
252
152
749
2.60
18.52
2.7
2.3
—
—
—
0
0
284
1872
2.54
18.27
6.8
4.6
6.5
6.6
mmol/l
0.51
272
1734
20
24
8.69
15.50
2.5
1.5
—
—
—
0
0
163
900
2.31
14.86
4.8
3.0
0.2
0.3
e6/l
1.46
130
668
70
257
3.06
14.66
7.0
9.9
121.4
122.8
g/l
0.23
65
250
86
357
2.76
14.39
6.3
6.7
105.5
104.0
mmol/l
1.85
86
352
23
36
6.69
14.24
1.0
1.1
—
—
—
0
0
90
385
2.69
14.20
5.6
6.1
1.0
1.1
mmol/l
1.37
83
356
234
1517
2.20
14.19
5.2
4.0
—
—
—
0
0
161
903
2.26
13.97
2.6
2.1
144.5
298.5
u/l
1.15
155
851
15
14
11.07
13.82
1.2
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
16
17
9.74
13.51
1.2
1.2
—
—
—
0
0
102
477
2.49
13.34
2.9
4.1
0.8
0.8
mmol/l
0.28
97
456
17
20
8.81
13.33
1.1
1.1
1.2
1.0
u/l
—
10
12
248
1683
2.13
12.92
6.1
6.2
10.2
11.1
umol/l
0.48
237
1597
188
1157
2.11
12.61
4.7
3.1
—
—
—
0
0
99
483
2.37
11.66
2.1
1.8
—
—
—
0
0
16
21
7.88
11.49
3.4
2.4
11.7
9.0
%
0.29
11
12
56
210
2.92
11.21
9.3
8.3
24.7
24.9
mmol/l
0.12
56
210
64
260
2.72
11.03
5.6
6.9
1.1
1.2
mmol/l
0.90
64
248
204
1356
1.96
10.51
4.8
4.5
35.3
36.2
g/l
1.25
194
1272
270
1983
1.98
10.28
11.6
9.1
4.3
4.0
e9/l
1.26
248
1734
15
22
7.03
9.79
3.5
2.3
—
—
—
0
0
12
14
8.79
9.39
1.1
1.1
—
—
—
0
0
45
174
2.77
8.49
10.9
9.5
25.7
24.6
mmol/l
1.18
38
164
173
1159
1.83
8.14
3.8
3.5
26.8
38.6
ng/l
0.70
118
739
68
331
2.25
7.88
2.1
1.6
—
—
—
0
0
69
338
2.24
7.88
2.1
1.7
—
—
—
0
0
27
82
3.45
7.65
1.8
1.4
—
—
—
0
0
61
287
2.31
7.65
5.5
4.5
1.6
1.8
mmol/l
0.14
52
226
62
302
2.23
7.16
3.9
3.1
—
—
—
0
0
91
517
1.97
7.00
1.7
1.6
1174.4
1204.8
nmol/l
0.10
77
398
50
228
2.35
6.73
1.9
2.1
68.4
67.4
g/l
0.66
45
210
64
324
2.15
6.71
2.4
4.1
232.0
250.0
u/l
0.59
54
306
309
2537
1.78
6.61
9.2
7.1
80.1
78.7
u/l
0.20
297
2376
39
163
2.53
6.33
1.9
1.7
—
—
—
0
0
38
158
2.54
6.23
6.0
5.2
23.7
23.8
mmol/l
0.06
33
142
94
564
1.85
6.07
4.5
2.5
1.7
1.0
e6/l
0.71
51
320
386
3452
2.20
5.75
23.6
12.5
19.8
22.2
mg/l
1.10
350
2642
72
403
1.95
5.73
3.3
2.3
20.6
23.1
%
0.83
65
351
118
771
1.73
5.69
2.0
1.8
0.8
1.2
mg/l
1.53
92
594
45
212
2.25
5.62
7.8
5.4
2.4
1.9
mmol/l
0.49
34
161
11
21
5.35
5.55
1.8
2.0
—
—
—
0
0
10
18
5.66
5.34
2.7
3.3
639.1
670.0
u/ml
—
10
18
87
529
1.81
5.34
4.7
2.7
2.4
2.6
e6/l
0.12
43
285
79
474
1.82
5.06
3.2
2.3
12.1
13.6
umol/l
0.92
74
440
117
792
1.66
4.86
3.0
2.1
3.1
3.1
mg/l
0.13
98
680
8
7
11.61
4.80
2.0
1.6
—
—
—
0
0
42
207
2.14
4.71
2.0
1.6
—
—
—
0
0
137
974
1.60
4.65
2.8
2.6
51.0
55.8
u/l
1.29
127
902
296
2504
1.59
4.63
5.1
4.0
12.2
11.1
mm/h
0.66
279
2312
15
44
3.50
4.50
1.2
1.5
0.5
0.5
nmol/l
0.14
15
39
306
2618
1.59
4.47
5.2
3.9
14.7
14.6
pmol/l
0.52
285
2412
207
1632
1.52
4.36
6.2
4.7
0.0
0.0
estimate
0.00
51
304
208
1649
1.51
4.22
4.5
3.5
0.0
0.0
estimate
0.50
51
293
18
62
2.99
4.22
1.7
1.5
—
—
—
0
0
205
1623
1.50
4.17
4.6
3.4
0.0
0.0
estimate
0.00
51
303
18
64
2.89
4.00
1.3
1.2
—
—
—
0
0
18
64
2.89
4.00
1.3
1.2
—
—
—
0
0
102
701
1.60
3.91
1.6
1.5
19.3
21.5
nmol/l
0.64
87
601
26
115
2.34
3.79
2.4
2.0
0.7
3.5
ug/l
0.60
17
104
16
55
2.98
3.77
3.4
3.9
3.5
4.3
e9/l
0.91
16
55
23
97
2.45
3.72
1.2
1.8
2.9
3.1
g/l
0.51
15
81
35
177
2.06
3.71
1.5
1.4
—
—
—
0
0
24
105
2.36
3.59
1.2
1.8
3.4
3.8
g/l
0.74
15
80
24
105
2.36
3.59
1.2
1.8
—
—
—
0
0
24
105
2.36
3.59
1.2
1.8
6.6
7.5
g/l
1.88
16
83
172
1344
1.47
3.59
2.8
2.3
74.4
75.2
nmol/l
0.17
152
1218
349
3137
1.61
3.59
5.9
4.6
1.7
2.2
mu/l
0.83
326
2883
16
57
2.88
3.56
3.4
4.3
55.6
57.1
%
0.15
16
57
6
6
10.12
3.50
1.2
8.5
—
—
—
0
0
148
1128
1.48
3.49
3.4
3.3
28.8
31.2
u/l
0.63
139
1079
21
89
2.43
3.37
2.1
2.7
—
—
—
0
0
29
143
2.10
3.29
1.2
1.3
0.2
3.1
u/ml
—
6
9
15
54
2.84
3.28
3.3
4.8
—
1137.4
—
0
5
6
7
8.67
3.27
1.2
1.0
—
—
—
0
0
6
7
8.67
3.27
1.2
1.0
—
—
—
0
0
112
817
1.50
3.24
1.3
1.3
0.9
1.8
u/ml
0.72
26
218
7
11
6.45
3.19
1.1
1.1
—
—
—
0
0
16
61
2.69
3.17
2.7
2.9
17.3
16.2
%
—
7
29
17
67
2.60
3.16
2.2
2.2
135.8
129.2
g/l
—
10
48
22
99
2.29
3.11
1.2
1.8
11.2
10.5
g/l
0.27
16
88
12
39
3.14
3.11
1.3
1.2
—
—
—
0
0
25
119
2.17
3.11
2.0
2.0
—
—
—
0
0
139
1067
1.45
3.10
2.9
3.2
2.4
2.4
mmol/l
0.07
122
950
28
140
2.07
3.08
5.0
3.8
55.4
49.5
%
0.55
28
140
155
1216
1.43
3.06
2.2
1.8
95.9
96.0
pmol/l
0.01
78
623
7
12
5.91
3.03
1.1
1.2
—
—
—
0
0
7
12
5.91
3.03
1.1
1.2
—
—
—
0
0
15
57
2.69
2.99
1.1
1.5
33.7
27.8
u/l
0.32
15
46
9
22
4.16
2.89
1.2
1.1
—
—
—
0
0
40
234
1.78
2.80
1.2
1.2
101.0
149.1
u/ml
0.64
35
215
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
74
2.35
2.61
3.8
3.6
0.3
0.3
u/ml
—
8
45
109
824
1.43
2.59
2.4
3.1
1201.1
1269.8
ng/l
0.05
88
695
86
622
1.48
2.57
1.7
1.7
460.4
436.3
pmol/l
0.35
77
528
6
11
5.51
2.55
1.2
1.0
—
—
—
0
0
12
45
2.71
2.47
1.2
1.1
—
—
—
0
0
182
1511
1.36
2.45
3.8
2.7
122.5
103.1
ug/l
0.53
166
1412
6
12
5.05
2.41
1.2
1.1
—
—
—
0
0
18
84
2.19
2.38
1.3
1.3
—
—
—
0
0
7
17
4.17
2.37
1.6
1.6
8.9
13.8
u/l
—
7
17
21
105
2.05
2.35
1.8
1.8
—
192.0
—
0
5
16
73
2.24
2.24
1.4
1.4
—
—
—
0
0
22
116
1.95
2.15
1.8
1.8
—
—
—
0
0
109
854
1.37
2.07
5.1
3.8
0.0
0.0
estimate
0.69
52
299
39
248
1.63
2.07
2.9
3.3
1.2
1.2
mmol/l
0.01
34
217
53
364
1.52
2.03
4.6
3.9
31.9
31.5
%
0.09
40
239
7
21
3.37
1.97
1.1
1.0
—
—
—
0
0
76
565
1.42
1.96
3.6
3.2
52.8
303.2
ng/l
1.96
54
412
55
384
1.50
1.96
2.7
3.1
9.2
7.0
umol/l
0.33
47
331
26
150
1.78
1.95
3.0
2.9
1.3
1.3
%
0.05
26
150
260
2321
1.31
1.95
4.2
3.1
63.8
43.3
u/l
1.74
244
2199
341
3169
1.37
1.90
19.5
11.5
86.5
84.5
ml/min/173m2
0.88
302
2588
5
12
4.20
1.83
1.2
1.4
—
—
—
0
0
385
3662
1.51
1.81
14.0
9.6
26.5
25.8
u/l
0.46
376
3539
13
61
2.17
1.73
1.2
1.5
0.2
0.3
nmol/l
—
7
45
5
13
3.88
1.72
1.0
2.9
97.2
134.0
ug/l
—
5
13
19
104
1.87
1.70
2.5
3.3
103.1
91.0
%
1.19
19
96
8
31
2.61
1.66
6.0
1.4
17.3
24.0
ug/l
—
8
31
149
1263
1.28
1.59
4.7
3.5
—
—
—
0
0
7
26
2.72
1.58
2.3
1.6
—
—
—
0
0
44
308
1.48
1.57
2.6
2.4
25.5
33.9
u/l
1.80
37
256
11
51
2.19
1.52
1.1
1.1
—
—
—
0
0
23
140
1.68
1.48
4.6
1.9
1381.7
2876.3
u/l
—
5
48
9
40
2.28
1.41
1.0
1.4
—
—
—
0
0
11
53
2.10
1.39
1.3
1.5
—
—
—
0
0
91
741
1.29
1.32
1.8
1.6
—
—
—
0
0
5
18
2.80
1.29
1.2
1.3
—
—
—
0
0
326
3067
1.26
1.27
5.9
5.3
39.8
39.3
mmol/mol
0.31
303
2873
344
3258
1.28
1.26
4.1
4.2
5.8
5.9
mmol/l
0.25
322
3008
17
101
1.71
1.21
1.1
1.2
—
—
—
0
0
13
71
1.86
1.20
1.6
1.4
—
—
—
0
0
399
3867
1.47
1.20
33.9
18.6
132.8
135.6
g/l
3.80
399
3820
10
185
0.53
1.18
1.9
1.5
—
—
—
0
0
17
102
1.69
1.18
1.1
1.2
—
—
—
0
0
11
57
1.95
1.18
1.4
1.5
—
—
—
0
0
5
20
2.52
1.15
1.0
2.0
—
—
—
0
0
5
20
2.52
1.15
1.0
2.0
—
—
—
0
0
258
2381
1.21
1.14
3.8
3.3
—
—
—
0
0
15
88
1.73
1.12
1.1
1.1
—
3.8
—
0
12
13
73
1.81
1.12
1.2
1.9
—
—
—
0
0
37
270
1.41
1.11
1.2
1.2
62.7
180.2
iu/ml
2.49
13
114
97
817
1.24
1.07
2.6
2.6
354.2
8758.7
umol/l
4.47
75
711
10
52
1.95
1.07
1.4
1.4
2.2
3.4
ug/l
—
5
45
17
106
1.63
1.04
1.5
1.1
—
—
—
0
0
49
382
1.32
0.99
9.9
6.1
—
—
—
0
0
11
61
1.82
0.99
1.1
1.1
—
—
—
0
0
9
50
1.82
0.97
1.0
1.1
—
—
—
0
0
46
357
1.32
0.97
14.2
22.2
1.0
1.3
inr
—
6
49
70
575
1.26
0.96
3.2
2.8
2.4
2.4
mmol/l
0.14
59
504
13
77
1.71
0.96
1.1
1.5
—
—
—
0
0
7
37
1.91
0.94
1.4
1.4
—
—
—
0
0
6
27
2.24
0.94
2.2
1.1
—
—
—
0
0
13
79
1.67
0.89
1.3
1.2
—
—
—
0
0
27
195
1.41
0.88
1.1
1.3
—
—
—
0
0
16
104
1.56
0.85
1.5
1.4
—
—
—
0
0
8
47
1.72
0.81
1.8
1.3
—
—
—
0
0
6
33
1.83
0.79
1.2
1.3
—
—
—
0
0
13
82
1.60
0.79
1.9
1.4
—
—
—
0
0
101
882
1.19
0.78
1.5
1.7
1.5
1.4
mmol/l
0.54
87
754
7
38
1.86
0.74
1.1
1.5
—
—
—
0
0
28
363
0.76
0.71
1.6
1.6
—
—
—
0
0
71
610
1.20
0.67
1.3
1.3
24.6
34.0
iu/ml
0.26
17
205
24
180
1.35
0.66
2.9
2.8
0.1
0.1
e6/l
0.20
24
173
5
28
1.79
0.66
2.2
1.1
—
—
—
0
0
5
28
1.79
0.66
2.2
1.1
—
—
—
0
0
5
28
1.79
0.66
2.0
1.5
1.4
1.0
g/l
—
5
28
0
20
0.00
0.60
0.0
5.3
—
39.4
—
0
5
6
35
1.72
0.58
3.0
4.1
—
—
—
0
0
6
35
1.72
0.58
1.8
1.6
—
—
—
0
0
6
39
1.55
0.53
1.3
1.6
—
—
—
0
0
68
602
1.15
0.47
1.3
1.3
2.9
12.9
u/ml
2.55
25
236
15
195
0.76
0.42
1.1
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
8.1
—
0
15
0
16
0.00
0.41
0.0
2.3
—
—
—
0
0
11
79
1.40
0.41
1.6
1.5
—
—
—
0
0
24
198
1.22
0.37
1.6
1.8
—
—
—
0
0
14
108
1.31
0.35
2.1
1.8
—
—
—
0
0
6
44
1.37
0.34
1.3
1.4
—
—
—
0
0
6
44
1.37
0.34
1.3
1.5
—
—
—
0
0
6
44
1.37
0.34
1.3
1.5
—
—
—
0
0
10
133
0.75
0.34
1.3
1.7
—
—
—
0
0
6
45
1.34
0.34
1.3
1.0
—
—
—
0
0
6
45
1.34
0.34
1.3
1.4
—
—
—
0
0
6
45
1.34
0.34
1.3
1.4
—
—
—
0
0
6
45
1.34
0.34
1.3
1.4
—
—
—
0
0
6
45
1.34
0.34
1.3
1.2
—
—
—
0
0
6
46
1.31
0.33
1.3
1.5
—
—
—
0
0
50
447
1.13
0.32
2.6
1.8
1.6
1.4
%
0.94
44
405
29
250
1.17
0.30
1.7
1.9
—
—
—
0
0
92
859
1.09
0.28
4.3
4.7
2.4
2.7
ug/l
0.24
80
764
16
132
1.22
0.26
1.3
1.5
—
—
—
0
0
331
3254
1.08
0.23
25.5
13.4
38.7
40.1
%
1.93
240
2515
5
38
1.32
0.23
1.4
1.6
—
—
—
0
0
48
522
0.91
0.22
3.3
2.8
0.9
0.8
ug/l
0.27
34
337
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
29
259
1.13
0.20
2.7
2.5
74.6
67.4
ml/min/173m2
0.51
16
108
67
627
1.08
0.20
1.4
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
95.4
—
0
8
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
14
0.00
0.20
0.0
1.0
—
131.7
—
0
14
0
14
0.00
0.20
0.0
1.0
—
113.5
—
0
8
15
127
1.19
0.20
1.3
2.4
—
—
—
0
0
14
118
1.19
0.19
1.9
1.3
—
—
—
0
0
6
52
1.16
0.19
1.2
1.2
—
—
—
0
0
7
58
1.21
0.18
1.4
1.5
—
—
—
0
0
8
70
1.15
0.16
1.1
3.0
—
3.0
—
0
9
44
472
0.92
0.16
2.3
2.0
—
—
—
0
0
9
80
1.13
0.15
1.3
1.4
—
—
—
0
0
39
418
0.93
0.14
2.3
1.9
—
—
—
0
0
12
137
0.87
0.12
1.2
1.3
105.6
256.6
miu/ml
—
5
68
14
124
1.13
0.11
2.4
1.4
—
—
—
0
0
12
135
0.89
0.10
1.7
1.4
—
—
—
0
0
29
308
0.94
0.08
2.9
4.5
10.1
44.9
ug/l
0.70
23
249
6
58
1.03
0.08
1.5
1.5
—
—
—
0
0
7
68
1.03
0.08
1.9
1.8
—
—
—
0
0
9
86
1.05
0.07
1.2
1.2
—
—
—
0
0
68
697
0.97
0.05
4.1
4.2
22.5
21.4
%
0.22
36
331
341
3422
0.98
0.03
4.7
4.6
2.8
2.8
mmol/l
0.17
319
3177
334
3349
0.99
0.01
4.4
4.1
1.4
1.5
mmol/l
2.64
310
3115
335
3356
0.99
0.00
4.4
4.2
4.7
4.7
mmol/l
0.44
314
3139
325
3249
1.00
0.00
4.0
3.7
1.4
1.3
mmol/l
1.20
302
3010
0
6
0.00
0.00
0.0
1.0
—
7.1
—
0
6
5
52
0.96
0.00
1.2
2.3
2.6
81.9
u/ml
—
5
47
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1.7
—
0
6
7
78
0.90
0.00
1.4
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
0.6
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
52.4
—
0
5
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
8
79
1.01
0.00
1.3
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_CNSOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CNSOTH | 2.546 [1.94, 3.33] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.811 |
During the follow-up period (1.1.1998 — 31.12.2019), 160 out of 1017 females with G6_CNSOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CNSOTH | 2.416 [1.86, 3.13] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.03 |
During the follow-up period (1.1.1998 — 31.12.2019), 195 out of 815 males with G6_CNSOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_CNSOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.256% | 0.513% |
| 5 | 1.547% | 2.716% |
| 10 | 3.976% | 7.605% |
| 15 | 7.418% | 14.388% |
| 20 | 12.607% | 23.066% |
Relationships between endpoints
↥Index endpoint: G6_CNSOTH – Other disorders of central nervous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data